GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » enVVeno Medical Corp (NAS:NVNO) » Definitions » Operating Income

enVVeno Medical (enVVeno Medical) Operating Income : $-23.94 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is enVVeno Medical Operating Income?

enVVeno Medical's Operating Income for the three months ended in Mar. 2024 was $-5.50 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.94 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. enVVeno Medical's Operating Income for the three months ended in Mar. 2024 was $-5.50 Mil. enVVeno Medical's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, enVVeno Medical's Operating Margin % for the quarter that ended in Mar. 2024 was %.

enVVeno Medical's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. enVVeno Medical's annualized ROC % for the quarter that ended in Mar. 2024 was -884.55%. enVVeno Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -1,362.55%.


enVVeno Medical Operating Income Historical Data

The historical data trend for enVVeno Medical's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

enVVeno Medical Operating Income Chart

enVVeno Medical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only -7.09 -9.14 -16.89 -24.93 -25.24

enVVeno Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.80 -6.81 -5.35 -6.28 -5.50

enVVeno Medical Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


enVVeno Medical  (NAS:NVNO) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

enVVeno Medical's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-22.012 * ( 1 - 0% )/( (2.656 + 2.321)/ 2 )
=-22.012/2.4885
=-884.55 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

enVVeno Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-22.012/( ( (1.681 + max(-0.522, 0)) + (1.55 + max(-0.837, 0)) )/ 2 )
=-22.012/( ( 1.681 + 1.55 )/ 2 )
=-22.012/1.6155
=-1,362.55 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.511) - (0.427 + 0 + 0.606)
=-0.522

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.306) - (0.747 + 0 + 0.396)
=-0.837

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

enVVeno Medical's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-5.503/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


enVVeno Medical Operating Income Related Terms

Thank you for viewing the detailed overview of enVVeno Medical's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


enVVeno Medical (enVVeno Medical) Business Description

Traded in Other Exchanges
Address
70 Doppler, Irvine, CA, USA, 92618
enVVeno Medical Corp is a medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
Executives
Hamed Alavi officer: Chief Technology Officer ENVVENO MEDICAL CORPORATION, 70 DOPPLER, IRVINE CA 92618
Francis Duhay director HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Sanjay Shrivastava director HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert Andrew Berman director, officer: CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Matthew Jenusaitis director 2 GOODYEAR, IRVINE CA 92618
Robert Gray director 70 DOPPLER, IRVINE CA 92618
Marc H. Glickman officer: See Remarks 70 DOPPLER, IRVINE CA 92618
Biodyne Holding, S.a. 10 percent owner 13 RUE DE LA GARE, MORGES V8 1110
Craig Glynn officer: Chief Financial Officer 70 DOPPLER, IRVINE CA 92618
Marcus W. Robins director C/O HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert A Rankin officer: Chief Financial Officer 9200 SUNSET BLVD., SUITE 425, WEST HOLLYWOOD CA 90069
Browston Trading Ltd 10 percent owner P.O. BOX 20533, NICOSIA G4 1660
Robert W. Doyle director 70 DOPPLER, IRVINE CA 92618
Robert A. Anderson director 70 DOPPLER, IRVINE CA 92618
Susan Montoya officer: See Remarks 70 DOPPLER, IRVINE CA 92618